The merger of datasets from other international centres running the MILI study (such as NIH which is adopting an identical protocol) will increase the statistical power by which we can explore TP53 mutation phenotypes, i.e. whether certain TP53 mutations correspond to specific cancer pathologies. The gene discussed is TP53; the disease is cancer.